ImaRx Pharma, DuPont deal

DuPont acquired ImaRx, a developer of ultrasound contrast agents, for cash and stock. Under a 1995 deal, the companies have developed Definity, a perflutren-based ultrasound contrast agent under review in Europe and the U.S. for imaging cardiac structure and function and imaging the liver and kidney. Yamanouchi Pharmaceutical Co. Ltd. (Tokyo, Japan) has marketing rights to the agent in Asia and will pay milestones and royalties to DuPont. ...